KHRN.V - Khiron Life Sciences Corp.

TSXV - TSXV Delayed Price. Currency in CAD
-0.0300 (-1.52%)
At close: 3:59PM EDT
Stock chart is not supported by your current browser
Previous Close1.9700
Bid1.9400 x 0
Ask1.9500 x 0
Day's Range1.9200 - 1.9800
52 Week Range0.8800 - 4.3500
Avg. Volume489,914
Market Cap214.259M
Beta (3Y Monthly)4.09
PE Ratio (TTM)N/A
EPS (TTM)-0.4360
Earnings DateMay 30, 2019 - May 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.58
  • CNW Group

    Khiron Provides Clarification of August 12, 2019 News Release

    TORONTO, Aug. 14, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV:KHRN.V - News), (OTCQB:KHRNF - News), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, wishes to clarify specific disclosure relating to the news release disseminated by the Company on August 12, 2019. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.

  • CNW Group

    Khiron Boosts European Expansion With Key Executive Appointments

    Experienced capital markets leader and cannabis industry executive Tejinder Virk is appointed President of Khiron Europe Accomplished cannabis legal expert Franziska Katterbach joins Company as Chief Legal ...

  • CNW Group

    Khiron Launches Revenue-Generating Pilot Program With Top Colombian Health Insurance Provider

    Four-month pilot program with EPS SURA represents first step towards an integrated healthcare system for priority neurological pathologies EPS SURA is Colombia's leading insurance provider and an affiliate ...

  • Baystreet

    Heightened Interest in Hemp-Infused Beauty Products as Large Conglomerates Enter Space

    As the wave of positive reviews roll in, hemp-infused beauty products containing the non-psychoactive ...